| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Aarhus N; 2 University Institute of Pathology, Aarhus University Hospital, Aarhus C; 3 Department of Theoretical Statistics, Department of Mathematical Sciences, Ny Munkegade, Aarhus C; and 4 Department of Urology, Aarhus University Hospital, Skejby, Aarhus N, Denmark
The presence of carcinoma in situ (CIS) lesions in the urinary bladder is associated with a high risk of disease progression to a muscle invasive stage. In this study, we used microarray expression profiling to examine the gene expression patterns in superficial transitional cell carcinoma (sTCC) with surrounding CIS (13 patients), without surrounding CIS lesions (15 patients), and in muscle invasive carcinomas (mTCC; 13 patients). Hierarchical cluster analysis separated the sTCC samples according to the presence or absence of CIS in the surrounding urothelium. We identified a few gene clusters that contained genes with similar expression levels in transitional cell carcinoma (TCC) with surrounding CIS and invasive TCC. However, no close relationship between TCC with adjacent CIS and invasive TCC was observed using hierarchical cluster analysis. Expression profiling of a series of biopsies from normal urothelium and urothelium with CIS lesions from the same urinary bladder revealed that the gene expression found in sTCC with surrounding CIS is found also in CIS biopsies as well as in histologically normal samples adjacent to the CIS lesions. Furthermore, we also identified similar gene expression changes in mTCC samples. We used a supervised learning approach to build a 16-gene molecular CIS classifier. The classifier was able to classify sTCC samples according to the presence or absence of surrounding CIS with a high accuracy. This study demonstrates that a CIS gene expression signature is present not only in CIS biopsies but also in sTCC, mTCC, and, remarkably, in histologically normal urothelium from bladders with CIS. Identification of this expression signature could provide guidance for the selection of therapy and follow-up regimen in patients with early stage bladder cancer.
This article has been cited by other articles:
|
|
 |
|
  H. Yang, C. P. Dinney, Y. Ye, Y. Zhu, H. B. Grossman, and X. Wu Evaluation of Genetic Variants in MicroRNA-Related Genes and Risk of Bladder Cancer Cancer Res., April 1, 2008; 68(7): 2530 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Xia, C. W. Lee, and D. C. Altieri Tumor Cell Dependence on Ran-GTP-Directed Mitosis Cancer Res., March 15, 2008; 68(6): 1826 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jin, X. Wang, J. Ying, A. H. Y. Wong, Y. Cui, G. Srivastava, Z.-Y. Shen, E.-M. Li, Q. Zhang, J. Jin, et al. Epigenetic silencing of a Ca2+-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers PNAS, July 24, 2007; 104(30): 12353 - 12358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Smith, G. Oxford, A. S. Baras, C. Owens, D. Havaleshko, D. L. Brautigan, M. K. Safo, and D. Theodorescu Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer Clin. Cancer Res., July 1, 2007; 13(13): 3803 - 3813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Dyrskjot, K. Zieger, F. X. Real, N. Malats, A. Carrato, C. Hurst, S. Kotwal, M. Knowles, P.-U. Malmstrom, M. de la Torre, et al. Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study Clin. Cancer Res., June 15, 2007; 13(12): 3545 - 3551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sanchez-Carbayo, N. D. Socci, J. Lozano, F. Saint, and C. Cordon-Cardo Defining Molecular Profiles of Poor Outcome in Patients With Invasive Bladder Cancer Using Oligonucleotide Microarrays J. Clin. Oncol., February 10, 2006; 24(5): 778 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Zieger, L. Dyrskjot, C. Wiuf, J. L. Jensen, C. L. Andersen, K. M.-E. Jensen, and T. F. Orntoft Role of Activating Fibroblast Growth Factor Receptor 3 Mutations in the Development of Bladder Tumors Clin. Cancer Res., November 1, 2005; 11(21): 7709 - 7719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Marsit, M. R. Karagas, A. Andrew, M. Liu, H. Danaee, A. R. Schned, H. H. Nelson, and K. T. Kelsey Epigenetic Inactivation of SFRP Genes and TP53 Alteration Act Jointly as Markers of Invasive Bladder Cancer Cancer Res., August 15, 2005; 65(16): 7081 - 7085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Wild, A. Herr, C. Wissmann, R. Stoehr, A. Rosenthal, D. Zaak, R. Simon, R. Knuechel, C. Pilarsky, and A. Hartmann Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder Clin. Cancer Res., June 15, 2005; 11(12): 4415 - 4429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ohlsson, J. M. A. Moreira, P. Gromov, G. Sauter, and J. E. Celis Loss of Expression of the Adipocyte-type Fatty Acid-binding Protein (A-FABP) Is Associated with Progression of Human Urothelial Carcinomas Mol. Cell. Proteomics, April 1, 2005; 4(4): 570 - 581. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
